$48.92
0.14% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US69366J2006
Symbol
PTCT

PTC Therapeutics, Inc. Stock price

$48.92
+1.06 2.21% 1M
-1.77 3.49% 6M
+3.78 8.37% YTD
+14.99 44.18% 1Y
-2.35 4.58% 3Y
+0.34 0.70% 5Y
+13.84 39.43% 10Y
+32.43 196.66% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+0.07 0.14%
ISIN
US69366J2006
Symbol
PTCT
Industry

Key metrics

Basic
Market capitalization
$3.9b
Enterprise Value
$4.3b
Net debt
$412.1m
Cash
$2.0b
Shares outstanding
79.4m
Valuation (TTM | estimate)
P/E
6.1 | 7.1
P/S
2.2 | 2.2
EV/Sales
2.4 | 2.4
EV/FCF
6.2
P/B
negative
Financial Health
Equity Ratio
-64.4%
Return on Equity
33.1%
ROCE
43.7%
ROIC
216.0%
Debt/Equity
-11.6
Financials (TTM | estimate)
Revenue
$1.8b | $1.8b
EBITDA
$891.3m | $857.1m
EBIT
$877.1m | $654.6m
Net Income
$629.2m | $549.0m
Free Cash Flow
$697.4m
Growth (TTM | estimate)
Revenue
96.0% | 120.4%
EBITDA
14,663.4% | 1,151.3%
EBIT
546.8% | 560.1%
Net Income
231.2% | 251.1%
Free Cash Flow
638.0%
Margin (TTM | estimate)
Gross
97.1%
EBITDA
50.5% | 48.2%
EBIT
49.7%
Net
35.7% | 30.9%
Free Cash Flow
39.5%
More
EPS
$8.1
FCF per Share
$8.8
Short interest
8.7%
Employees
939
Rev per Employee
$860.0k
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a PTC Therapeutics, Inc. forecast:

16x Buy
70%
6x Hold
26%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
70%
Hold
26%
Sell
4%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,765 1,765
96% 96%
100%
- Direct Costs 51 51
25% 25%
3%
1,714 1,714
106% 106%
97%
- Selling and Administrative Expenses 324 324
8% 8%
18%
- Research and Development Expense 508 508
5% 5%
29%
891 891
14,663% 14,663%
50%
- Depreciation and Amortization 14 14
93% 93%
1%
EBIT (Operating Income) EBIT 877 877
547% 547%
50%
Net Profit 629 629
231% 231%
36%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about 21 hours ago
WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 2025 Wednesday, Sept.
Positive
Seeking Alpha
one day ago
Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votopl...
Negative
Reuters
3 days ago
The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday, delaying a potential treatment for patients with limited treatment options.
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 939
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today